A citation-based method for searching scientific literature

Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Désirée van der Heijde, Philip J Mease. Arthritis Rheumatol 2022
Times Cited: 10







List of co-cited articles
40 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
106
70

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
108
70

Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Xie L Xu, Ramanand A Subramanian, Prasheen Agarwal, Shihong Sheng,[...]. Arthritis Rheumatol 2021
18
60

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Enrique R Soriano, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu,[...]. RMD Open 2021
13
60

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
307
40

The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
Richard G B Langley, Steven R Feldman, Judit Nyirady, Peter van de Kerkhof, Charis Papavassilis. J Dermatolog Treat 2015
123
40

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
613
40

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair,[...]. Rheumatology (Oxford) 2021
19
30

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Laura C Coates, Arthur Kavanaugh, Philip J Mease, Enrique R Soriano, Maria Laura Acosta-Felquer, April W Armstrong, Wilson Bautista-Molano, Wolf-Henning Boehncke, Willemina Campbell, Alberto Cauli,[...]. Arthritis Rheumatol 2016
539
30

International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis.
Dafna D Gladman, Robert D Inman, Richard J Cook, Walter P Maksymowych, Jurgen Braun, John C Davis, Robert B M Landewé, Philip Mease, Joachim Brandt, Ruben Burgos Vargas,[...]. J Rheumatol 2007
99
30

Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis.
Vinod Chandran, Sita Bhella, Catherine Schentag, Dafna D Gladman. Ann Rheum Dis 2007
120
30


Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era.
Dafna D Gladman, Olga Ziouzina, Arane Thavaneswaran, Vinod Chandran. J Rheumatol 2013
60
30

Severe psoriasis--oral therapy with a new retinoid.
T Fredriksson, U Pettersson. Dermatologica 1978
30

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
Laura C Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S Karyekar, May Shawi, Wim Noël, Georg Schett, Iain B McInnes. Ann Rheum Dis 2022
7
42

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Wolf-Henning Boehncke, Nicolo Costantino Brembilla, Michael John Nissen. Expert Rev Clin Immunol 2021
14
30

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
224
20

Measurement of patient outcome in arthritis.
J F Fries, P Spitz, R G Kraines, H R Holman. Arthritis Rheum 1980
20

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
256
20

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
Leslie R Harrold, Bradley S Stolshek, Sabrina Rebello, David H Collier, Alex Mutebi, Sally W Wade, Wendi Malley, Jeffrey D Greenberg, Carol J Etzel. Clin Rheumatol 2017
28
20


Switching biologics in the treatment of psoriatic arthritis.
Joseph F Merola, Benjamin Lockshin, Elinor A Mody. Semin Arthritis Rheum 2017
51
20


Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
Proton Rahman, Philip J Mease, Philip S Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P Kollmeier, Elizabeth C Hsia, Bei Zhou, Xiwu Lin,[...]. Arthritis Res Ther 2021
3
66


Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants. Arthritis Rheum 2006
20

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
L C Coates, D D Gladman, P Nash, O FitzGerald, A Kavanaugh, T K Kvien, L Gossec, V Strand, L Rasouliyan, L Pricop,[...]. Arthritis Res Ther 2018
21
20

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Dafna D Gladman, Philip J Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Stephen Xu, Sean T Quinn, Cinty Gong, Evan Leibowitz,[...]. Trials 2022
2
100

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.
Arthur Kavanaugh, Lluís Puig, Alice B Gottlieb, Christopher Ritchlin, Shu Li, Yuhua Wang, Alan M Mendelsohn, Michael Song, Yaowei Zhu, Proton Rahman,[...]. Arthritis Care Res (Hoboken) 2015
67
20

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
C Antoni, G G Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, L T Dooley, A Kavanaugh. Ann Rheum Dis 2005
523
20

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Philip J Mease, Dafna D Gladman, Christopher T Ritchlin, Eric M Ruderman, Serge D Steinfeld, Ernest H S Choy, John T Sharp, Peter A Ory, Renee J Perdok, Mark A Weinberg. Arthritis Rheum 2005
686
20

Real-life efficacy of guselkumab in patients with early psoriatic arthritis.
Ilenia Pantano, Daniele Mauro, Francesca Romano, Alessio Gambardella, Mario Valenti, Davide Simone, Daniela Iacono, Antonio Costanzo, Giuseppe Argenziano, Francesco Ciccia. Rheumatology (Oxford) 2022
6
33

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Philip J Mease, Alan J Kivitz, Francis X Burch, Evan L Siegel, Stanley B Cohen, Peter Ory, David Salonen, Joel Rubenstein, John T Sharp, Wayne Tsuji. Arthritis Rheum 2004
690
20

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
536
20

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
315
20

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Rheumatol 2019
191
20

Treatment guidelines in psoriatic arthritis.
Alexis Ogdie, Laura C Coates, Dafna D Gladman. Rheumatology (Oxford) 2020
57
20

The Epidemiology of Psoriatic Arthritis.
Alexis Ogdie, Pamela Weiss. Rheum Dis Clin North Am 2015
232
20

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lu, Zailong Wang, Ahmed M Soliman,[...]. Ann Rheum Dis 2022
17
20

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb,[...]. Ann Rheum Dis 2022
19
20

Being overweight is associated with not reaching low disease activity in women but not men with psoriatic arthritis.
Michelle L M Mulder, Mark H Wenink, Johanna E Vriezekolk. Rheumatology (Oxford) 2022
2
50


Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers.
Pil Højgaard, Christine Ballegaard, René Cordtz, Kristian Zobbe, Marianne Clausen, Bente Glintborg, Lars Erik Kristensen, Lene Dreyer. Rheumatology (Oxford) 2018
30
10

Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Bente Glintborg, Mikkel Ostergaard, Niels Steen Krogh, Martin Dehn Andersen, Ulrik Tarp, Anne Gitte Loft, Hanne M Lindegaard, Mette Holland-Fischer, Henrik Nordin, Dorte Vendelbo Jensen,[...]. Arthritis Rheum 2013
124
10

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.
Amr A Saad, Darren M Ashcroft, Kath D Watson, Kimme L Hyrich, Peter R Noyce, Deborah P M Symmons. Arthritis Res Ther 2009
153
10


Psoriatic arthritis.
Vanessa Ocampo D, Dafna Gladman. F1000Res 2019
55
10

Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
Arthur Kavanaugh, Iain B McInnes, Philip J Mease, Stephen Hall, Hector Chinoy, Alan J Kivitz, Zailong Wang, Shephard Mpofu. J Rheumatol 2016
61
10

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.
Bente Glintborg, Mikkel Østergaard, Lene Dreyer, Niels Steen Krogh, Ulrik Tarp, Michael Sejer Hansen, Signe Rifbjerg-Madsen, Tove Lorenzen, Merete Lund Hetland. Arthritis Rheum 2011
175
10

Quality of life in psoriatic arthritis.
Tania Gudu, Laure Gossec. Expert Rev Clin Immunol 2018
72
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.